Aging does not lessen the effectiveness of TGFbeta2-enhanced bone regeneration

Area of Science:

• Orthopedics
• Regenerative Medicine
• Gerontology

Background:

• Concerns exist regarding the efficacy of bone healing and growth factor treatments in the aged skeleton.
• Understanding age-related differences in bone regeneration is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the effectiveness of recombinant human TGFbeta2 (rhTGFbeta2) in promoting bone regeneration in skeletally mature versus aged beagles.
• To determine if age impacts the response to bone-stimulating growth factors.

Main Methods:

• A standardized intramembranous bone regeneration model was used in 30 beagles (young and old).
• Titanium implants with a 3-mm gap were placed in the proximal humerus, with some treated with varying doses of rhTGFbeta2.
• Bone regeneration was assessed using backscatter scanning electron microscopy.

Main Results:

• rhTGFbeta2 significantly increased new bone volume (3-fold) and osteoblast surface (5-fold) at a dose of 35 microg in both young and old animals.
• Age did not significantly alter the quantity of new bone formed.
• Older animals exhibited thinner, more closely spaced trabeculae and increased osteoid, suggesting potential mineralization delays.

Conclusions:

• Recombinant human TGFbeta2 (rhTGFbeta2) is effective in enhancing bone regeneration in aged animals.
• While bone quantity is similar, qualitative differences in bone structure and mineralization may exist in older animals.
• These findings support the potential of rhTGFbeta2 for treating bone defects across different age groups.